Saurabh Saha | |
|---|---|
| Nationality | American |
| Education | BSc, MSc, MD, and PhD |
| Alma mater | California Institute of Technology Johns Hopkins University Harvard University University of Oxford |
| Occupation | Cancer drug discovery |
| Known for | Translational medicine Cancer biosurgery |
Saurabh Saha is an American biotech entrepreneur. [1]
Saha received his undergraduate degree in biology from the California Institute of Technology. [2] He also attended both Harvard Business School and Oxford University. [3] Saha trained under Bert Vogelstein during his studies at the Johns Hopkins School of Medicine, [4] where he received both an MD and a PhD in cancer genetics. [5]
After finishing graduate school, Saha joined the management consulting firm McKinsey & Company in their Pharmaceuticals and Medical Products Practice in New York City. [6] In 2005, he became the Director of the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research based in Cambridge, Massachusetts. [5] Between 2008 and 2015, Saha served as the President of BioMed Valley Discoveries [7] [3] Saha serves as a venture partner for the life sciences venture capital firm, Atlas Venture and also served as the Chief Medical Officer for its portfolio company, Synlogic. [8]
In 2016, Saha was appointed as President and CEO of Delinia, a biotech company focused on developing novel therapies for the treatment of cancer and autoimmune diseases such as lupus, inflammatory bowel disease, rheumatoid arthritis and others. [9] [10] [11]
Saha has published in periodicals where he and his colleagues reported translational research and development discoveries in cancer research. [12] [13] [14] [15] [16] [17] [18] He is also on the editorial boards of the American Journal of Clinical Oncology, [19] Journal of Translational Medicine, [20] and Cancer Biology & Therapy. [21]